Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosis

Author:

Saiman Lisa12ORCID,Waters Valerie3ORCID,LiPuma John J.4ORCID,Hoffman Lucas R.56,Alby Kevin7,Zhang Sean X.8ORCID,Yau Yvonne C.9,Downey Damian G.10,Sermet-Gaudelus Isabelle11,Bouchara Jean-Philippe12,Kidd Timothy J.1314,Bell Scott C.1516ORCID,Brown A. Whitney1718

Affiliation:

1. Department of Pediatrics, Columbia University Irving Medical Center, New York, New York, USA

2. Department of Infection Prevention and Control, NewYork-Presbyterian Hospital, New York, New York, USA

3. Division of Infectious Diseases, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada

4. Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan, USA

5. Department of Pediatrics, University of Washington, Seattle, Washington, USA

6. Department of Microbiology, University of Washington, Seattle, Washington, USA

7. Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA

8. Division of Medical Microbiology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

9. Division of Microbiology, Department of Paediatric Laboratory Medicine, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada

10. Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University, Belfast, Ireland

11. Université de Paris Cité, Hôpital Necker-Enfants Malades, Assistance Publique, Paris, France

12. University of Angers-University of Brest, Infections Respiratoires Fongiques, Angers, France

13. Microbiology Division, Pathology Queensland Central Laboratory, The University of Queensland, Brisbane, Australia

14. School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia

15. The Prince Charles Hospital, Faculty of Medicine, The University of Queensland, Brisbane, Australia

16. The Translational Research Institute, Brisbane, Australia

17. Cystic Fibrosis Foundation, Bethesda, Maryland, USA

18. Inova Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, Virginia, USA

Abstract

SUMMARY This guidance presents recommendations for clinical microbiology laboratories for processing respiratory samples from people with cystic fibrosis (pwCF). Appropriate processing of respiratory samples is crucial to detect bacterial and fungal pathogens, guide treatment, monitor the epidemiology of cystic fibrosis (CF) pathogens, and assess therapeutic interventions. Thanks to CF transmembrane conductance regulator modulator therapy, the health of pwCF has improved, but as a result, fewer pwCF spontaneously expectorate sputum. Thus, the collection of sputum samples has decreased, while the collection of other types of respiratory samples such as oropharyngeal and bronchoalveolar lavage samples has increased. To optimize the detection of microorganisms, including Pseudomonas aeruginosa , Staphylococcus aureus , Haemophilus influenzae , and Burkholderia cepacia complex; other less common non-lactose fermenting Gram-negative bacilli, e.g., Stenotrophomonas maltophilia , Inquilinus , Achromobacter , Ralstonia , and Pandoraea species; and yeasts and filamentous fungi, non-selective and selective culture media are recommended for all types of respiratory samples, including samples obtained from pwCF after lung transplantation. There are no consensus recommendations for laboratory practices to detect, characterize, and report small colony variants (SCVs) of S. aureus , although studies are ongoing to address the potential clinical impact of SCVs. Accurate identification of less common Gram-negative bacilli, e.g., S. maltophilia , Inquilinus , Achromobacter , Ralstonia , and Pandoraea species, as well as yeasts and filamentous fungi, is recommended to understand their epidemiology and clinical importance in pwCF. However, conventional biochemical tests and automated platforms may not accurately identify CF pathogens. MALDI-TOF MS provides excellent genus-level identification, but databases may lack representation of CF pathogens to the species-level. Thus, DNA sequence analysis should be routinely available to laboratories for selected clinical circumstances. Antimicrobial susceptibility testing (AST) is not recommended for every routine surveillance culture obtained from pwCF, although selective AST may be helpful, e.g., for unusual pathogens or exacerbations unresponsive to initial therapy. While this guidance reflects current care paradigms for pwCF, recommendations will continue to evolve as CF research expands the evidence base for laboratory practices.

Publisher

American Society for Microbiology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3